• Explore /
  • Poster
  • / STEAM: A randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) versus FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC).

STEAM: A randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) versus FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC).

Abstract Poster

Authors

null

Johanna C. Bendell

The Sarah Cannon Research Institute, Nashville, TN

Johanna C. Bendell , Benjamin R. Tan Jr., James Andrew Reeves , Henry Q. Xiong , Rita Laeufle , Michelle Byrtek , Nicolas Sommer , Herbert Hurwitz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer

Clinical Trial Registration Number

NCT01765582

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr TPS3652)

DOI

10.1200/jco.2014.32.15_suppl.tps3652

Abstract #

TPS3652

Poster Bd #

113A

Abstract Disclosures

Similar Posters

First Author: Hideaki Bando

First Author: Zhichao Jiang

First Author: Sherise C. Rogers

First Author: Sherise C. Rogers